The terms for licensing Progenza will be key to the significance of the re rate. If they can manage to announce a deal for Sygenus at the same time or at least in the near term, this will go bonkers. There is some interesting analyst coverage on their website that values RGS at over $0.80 to $1.00 per share depending on the outcome of these deals. Take these reports with a grain of salt, but they make for an interesting read. This stock has been sleepy for ages. When it goes it will go pretty hard in my view.
RGS Price at posting:
12.0¢ Sentiment: Buy Disclosure: Held
